IRC
BDTX icon

Investors Research Corp’s Black Diamond Therapeutics BDTX Stock Holding History

Investors Research Corp’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30
Closed -$54 – 1129
2022
Q4 		$54 Hold
30
– – ﹤0.01% 1126
2022
Q3 		$0 Hold
30
– – ﹤0.01% 1088
2022
Q2 		$0 Hold
30
– – ﹤0.01% 1084
2022
Q1 		$0 Hold
30
– – ﹤0.01% 1024
2021
Q4 		$0 Hold
30
– – ﹤0.01% 988
2021
Q3 		$0 Hold
30
– – ﹤0.01% 995
2021
Q2 		$0 Hold
30
– – ﹤0.01% 978
2021
Q1 		$1K Sell
30
-5
-14% -$135 ﹤0.01% 917
2020
Q4 		$1K Hold
35
– – ﹤0.01% 1017
2020
Q3 		$1K Buy
+35
New +$1.06K ﹤0.01% 1025

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Investors Research Corp's BDTX Position: Q1 2023 in Review

Investors Research Corp sold out of Black Diamond Therapeutics (BDTX) in Q1 2023, closing a stake of 30 shares — an estimated $54 sold.

Investors Research Corp first reported a position in BDTX in Q3 2020 and held it in 10 quarters. The position peaked at $1K in Q1 2021. 50 funds tracked by Wall St. Rank hold BDTX as of Q1 2023.

  • Investors Research Corp reported no remaining Black Diamond Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Investors Research Corp sold 30 Black Diamond Therapeutics shares in Q1 2023, an estimated $54.
  • Investors Research Corp first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 10 quarters.
  • Investors Research Corp's Black Diamond Therapeutics position peaked at $1K in Q1 2021.
  • 50 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2023.

Based on Investors Research Corp's 13F filing for Q1 2023, filed 11 May 2023.